<DOC>
	<DOCNO>NCT00072709</DOCNO>
	<brief_summary>This global multicenter study design evaluate safety clinical effect 4 oral dos TCH346 ( 1.0 , 2.5 , 7.5 , 15 mg ) compare placebo patient mild mild moderate stage ALS . The study consist 3 phase : screening ( 2 week ) , run-in ( 16 week ) , double-blind treatment phase variable duration ( least 24 week ) .</brief_summary>
	<brief_title>Study Evaluating TCH346 Placebo Administered Once Daily Patients With Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Inclusion criterion : clinical diagnosis laboratorysupported probable , probable , definite ALS ; sporadic familial ALS ; ALS symptom onset 3 yr study entry ; FVC equal 70 % ; patient either riluzole naive patient receive concomitant treatment riluzole stable dose riluzole ( 50 mg bid ) study start . Exclusion criterion : Known suspect chronic infectious disease include HIV , hepatitis B , hepatitis C. Clinically significant ECG abnormality . Known hypersensitivity study drug relate drug ( e.g . selegiline , MAOA B inhibitor , tricyclic antidepressant ) . Patients treat potent inhibitor CYP1A2 CYP3A4 ( list inhibitor provide investigator ) . Treatment MAOA B inhibitor ( include selegiline ) within past 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>ALS</keyword>
	<keyword>Lou Gehrig 's disease</keyword>
</DOC>